Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Algernon Pharmaceuticalsinc (AGN.CN)

Algernon Pharmaceuticalsinc (AGN.CN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 23,413
  • Shares Outstanding, K 90,052
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta -0.37
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.13
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.04
  • Most Recent Earnings -0.01 on 02/29/20
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.180 +44.44%
on 06/29/20
0.290 -10.34%
on 07/07/20
-0.010 (-3.70%)
since 06/10/20
3-Month
0.180 +44.44%
on 06/29/20
0.580 -55.17%
on 04/30/20
-0.030 (-10.34%)
since 04/09/20
52-Week
0.040 +550.00%
on 11/27/19
0.580 -55.17%
on 04/30/20
+0.050 (+23.81%)
since 07/10/19

Most Recent Stories

More News
Biotechs Seek Solutions in the Face of Global Economic Upheaval

The consequences of the current pandemic are vast and complex for business stakeholders and customers alike, as international and local supply chains are under unparalleled economic pressure. Numerous...

AGNPF : 0.1922 (-3.90%)
AGN.CN : 0.260 (-3.70%)
VIR : 48.71 (+3.20%)
NVAX : 94.36 (-2.01%)
CODX : 18.19 (+1.00%)
MRNA : 62.61 (-3.63%)
Pharmaceutical Development Ramp up as Viral Infections Continue to Threaten

The global pharmaceutical contract development and manufacturing industry is driven by various major factors; these include the rising demand for generics, the increasing investments in pharmaceutical...

AGNPF : 0.1922 (-3.90%)
AGN.CN : 0.260 (-3.70%)
NVAX : 94.36 (-2.01%)
MRNA : 62.61 (-3.63%)
OPK : 4.02 (unch)
IBIO : 2.22 (-2.63%)
Algernon Pharmaceuticals Announces OTC Trading Symbol Change to AGNPF

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the "Company" or "Algernon") a clinical stage pharmaceutical development company is pleased to announced today that the Financial...

AGN.CN : 0.260 (-3.70%)
AGNPF : 0.1922 (-3.90%)
Algernon Pharmaceuticals Appoints Leading Respirologist Dr. Martin Kolb to Its Medical and Scientific Advisory Board

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the "Company" or "Algernon"), a clinical stage pharmaceutical development company, is pleased to announce that Dr. Martin Kolb,...

AGN.CN : 0.260 (-3.70%)
BTHCF : 0.0363 (-11.46%)
Algernon Pharmaceuticals to Present at 12th Annual LD Micro Main Event Conference on Wednesday December 11, 2019

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the "Company" or "Algernon"), a clinical stage pharmaceutical development company, is pleased to announce that it will present at...

AGN.CN : 0.260 (-3.70%)
BTHCF : 0.0363 (-11.46%)
Algernon Pharmaceuticals Selects NP-120 (Ifenprodil) for its Lead Phase 2 Trial for Idiopathic Pulmonary Fibrosis and Chronic Cough

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the "Company" or "Algernon"), a clinical stage pharmaceutical development company, is pleased to announce that it plans to conduct...

AGN.CN : 0.260 (-3.70%)
BTHCF : 0.0363 (-11.46%)
Algernon Pharmaceuticals' NP-120 (Ifenprodil) Outperforms Merck's Phase 3 Drug MK-7264 (Gefapixant) in an Acute Cough Study by 110%

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the "Company" or "Algernon"), a clinical stage pharmaceutical development company, is pleased to announce that NP-120 (Ifenprodil),...

MRK : 76.73 (+0.05%)
AGN.CN : 0.260 (-3.70%)
BTHCF : 0.0363 (-11.46%)
Algernon Pharmaceuticals Provides Update on its Planned Phase II Clinical Trial

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the "Company" or "Algernon"), a clinical stage pharmaceutical development company, is pleased to provide an update to the market...

AGN.CN : 0.260 (-3.70%)
BTHCF : 0.0363 (-11.46%)
Algernon Announces Closing of $2.07 Million Prospectus Offering of Units

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

AGN.CN : 0.260 (-3.70%)
BTHCF : 0.0363 (-11.46%)
Algernon Announces Pricing and Filing of Amended and Restated Prospectus

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

AGN.CN : 0.260 (-3.70%)
BTHCF : 0.0363 (-11.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Key Turning Points

2nd Resistance Point 0.287
1st Resistance Point 0.273
Last Price 0.260
1st Support Level 0.248
2nd Support Level 0.237

See More

52-Week High 0.580
Fibonacci 61.8% 0.374
Fibonacci 50% 0.310
Last Price 0.260
Fibonacci 38.2% 0.246
52-Week Low 0.040

See More

Business Summary

Algernon Pharmaceuticals Inc is a Canada based clinical stage drug development company focused on the areas of non-alcoholic steatohepatitis (NASH), chronic kidney disease (CKD) and inflammatory bowel disease (IBD). The company has two segments, the development centre of health-related technology in...

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar